Puthawala A A, Syed A M, Eads D L, Gillin L, Gates T C
Division of Radiation Oncology, University of California, Irvine.
Int J Radiat Oncol Biol Phys. 1988 May;14(5):839-48. doi: 10.1016/0360-3016(88)90003-x.
A total of 70 patients with histologically proven diagnosis of carcinoma of the base of the tongue were treated with primary irradiation between May 1974 through April 1984. Fifty-eight (83%) of these patients had locally advanced tumors (Stage T3, T4, N2, N3). Fifty-one of the 70 (73%) patients had clinically palpable neck nodes at first presentation. All patients received a combination of external and interstitial irradiation. The dose of external irradiation was limited to 45-50 Gy over 4 1/2-5 1/2 weeks. Interstitial volume implants were performed 2-3 weeks after completion of external irradiation. The primary site as well as the vallecula, epsilateral pharyngeal wall, glossopalatine sulcus, tonsillar bed, and pillars were routinely implanted to encompass contiguous spread of the disease. The doses of implant varied according to the stage of disease, that is, 2000-2500 cGy for T1 and T2 lesions, 3000-4000 cGy for T3 and T4 lesions, with typical dose rates of 50-60 cGy per hour. The neck nodes were also separately implanted to deliver additional doses of 2000-4000 cGy in 50-80 hours. Overall, local tumor control was observed in 58 of 70 (83%) patients at minimum follow-up of 2 years. An absolute 3-year disease-free survival of the entire group was 67.0%. Treatment related complications such as soft tissue necrosis and/or osteoradionecrosis occurred in 8 of the 70 (11.4%) patients. The salvage of neck failures and the local failures was feasible in 74% and 46% of the patients, respectively either by surgery or by re-irradiation using interstitial 192iridium implant alone. This treatment region is well tolerated and it preserves the functional and asthetic integrity in most patients.
1974年5月至1984年4月期间,共有70例经组织学确诊为舌根癌的患者接受了根治性放疗。其中58例(83%)患者患有局部晚期肿瘤(T3、T4、N2、N3期)。70例患者中有51例(73%)初诊时颈部淋巴结可触及。所有患者均接受外照射和组织间照射联合治疗。外照射剂量在4.5至5.5周内限制为45 - 50 Gy。组织间植入在完成外照射后2 - 3周进行。原发部位以及会厌谷、同侧咽壁、舌腭沟、扁桃体床和咽柱常规植入,以涵盖疾病的连续扩散。植入剂量根据疾病分期而有所不同,即T1和T2病变为2000 - 2500 cGy,T3和T4病变为3000 - 4000 cGy,典型剂量率为每小时50 - 60 cGy。颈部淋巴结也单独植入,在50 - 80小时内给予额外2000 - 4000 cGy的剂量。总体而言,在至少2年的随访中,70例患者中有58例(83%)实现了局部肿瘤控制。整个组的绝对3年无病生存率为67.0%。70例患者中有8例(11.4%)发生了与治疗相关的并发症,如软组织坏死和/或放射性骨坏死。颈部复发和局部复发的挽救分别在74%和46%的患者中可行,可通过手术或单独使用组织间192铱植入再照射来实现。该治疗区域耐受性良好,在大多数患者中保留了功能和美学完整性。